By Counterforce Health Team in Uptravi (selexipag) —

If Uptravi (Selexipag) Isn't Approved by UnitedHealthcare in North Carolina: Formulary Alternatives & Exception Paths

Answer Box: When UnitedHealthcare Denies Uptravi (Selexipag) in North Carolina

UnitedHealthcare requires step therapy before approving Uptravi (selexipag) for pulmonary arterial hypertension. You'll need to try formulary alternatives first—typically PDE5 inhibitors (sildenafil, tadalafil) or endothelin receptor antagonists (ambrisentan, bosentan)—unless you qualify for an exception. If denied after trying alternatives, use North Carolina's Smart NC external review program within 120 days. Contact Smart NC at 1-855-408-1212 for free advocacy support.

Table of Contents

When Formulary Alternatives Make Sense

UnitedHealthcare's step therapy requirements aren't arbitrary—they reflect established PAH treatment guidelines that recommend starting with certain drug classes before advancing to prostacyclin pathway agents like Uptravi. For many patients, these alternatives can be genuinely effective and may offer advantages in terms of access, monitoring requirements, and cost.

The key is understanding when alternatives are clinically appropriate versus when you need to push for an exception. If you have WHO Group I pulmonary arterial hypertension with functional class II-IV symptoms, you're likely a candidate for multiple treatment approaches.

Note: This guidance applies to fully insured UnitedHealthcare plans in North Carolina. Self-funded employer plans may have different requirements.

Coverage at a Glance

Requirement What It Means Where to Find It
Prior Authorization Required for all PAH drugs UHC Provider Portal
Step Therapy Try alternatives first OptumRx formulary documents
Specialist Prescriber Cardiologist, pulmonologist, or rheumatologist PA requirement forms
Diagnosis Documentation Right heart catheterization confirming WHO Group I PAH Medical necessity criteria
Appeals Deadline 180 days from denial (internal) UHC member materials
External Review 120 days after final internal denial Smart NC

UnitedHealthcare's Required PAH Alternatives

Based on OptumRx formulary requirements, UnitedHealthcare typically requires you to try these alternatives before approving Uptravi:

First-Line Options (Preferred)

PDE5 Inhibitors:

  • Sildenafil (Revatio, generic)
  • Tadalafil (Adcirca, Alyq)

Endothelin Receptor Antagonists:

  • Ambrisentan (Letairis)
  • Bosentan (Tracleer)

Second-Line Options

Other Prostacyclin Pathway Agents:

  • Treprostinil (Orenitram oral, Tyvaso inhaled)
  • Epoprostenol (IV infusion)
  • Iloprost (Ventavis inhaled)

Newer Agents:

  • Macitentan (Opsumit)
  • Macitentan/tadalafil combination (Opsynvi)
Clinician Corner: When submitting PA requests, include specific documentation about why preferred alternatives aren't appropriate—contraindications, previous failures, or intolerance with dates and clinical details.

Pros and Cons of Each Alternative

Understanding the trade-offs helps you and your provider make informed decisions about which alternatives to try first.

PDE5 Inhibitors (Sildenafil, Tadalafil)

Pros:

  • Oral administration, easier access
  • Lower monitoring requirements
  • Established safety profile
  • Often first-line per guidelines

Cons:

  • Contraindicated with nitrates
  • Blood pressure monitoring needed
  • May not be sufficient for severe PAH
  • Drug interactions with CYP3A4 inhibitors

Endothelin Receptor Antagonists

Ambrisentan (Letairis):

Pros:

  • Once-daily dosing
  • Lower hepatotoxicity risk than bosentan
  • No drug-drug interactions with warfarin

Cons:

  • Monthly liver function monitoring required
  • Teratogenic (pregnancy testing required)
  • Risk of anemia
  • Fluid retention possible

Bosentan (Tracleer):

Pros:

  • Extensive clinical experience
  • Twice-daily dosing

Cons:

  • Monthly liver function tests mandatory
  • More drug interactions (CYP3A4)
  • REMS program requirements
  • Contraindicated with cyclosporine

Prostacyclin Pathway Alternatives

Treprostinil (Orenitram, Tyvaso):

Pros:

  • Multiple formulations available
  • Can be combined with other PAH drugs
  • Strong efficacy data

Cons:

  • Complex dosing/titration
  • Side effects similar to Uptravi
  • Inhaled forms require specific devices
  • Higher cost than oral alternatives

Exception Strategy: Bypassing Step Therapy

You can request a step therapy exception if alternatives aren't appropriate for your specific situation. Success requires detailed clinical documentation.

Strong Exception Criteria

  1. Medical Contraindications:
    • Nitrate use (excludes PDE5 inhibitors)
    • Severe hepatic impairment (excludes ERAs)
    • Drug allergies or hypersensitivity
  2. Previous Treatment Failures:
    • Documented trials with specific drugs, dates, and reasons for discontinuation
    • Adverse events that required stopping therapy
    • Lack of efficacy with objective measures
  3. Clinical Urgency:
    • Rapidly progressing PAH
    • Functional class IV symptoms
    • Recent PAH-related hospitalization

Documentation Checklist

Your provider should include:

  • Diagnosis confirmation: Right heart catheterization results
  • Contraindication details: Specific medical reasons alternatives won't work
  • Previous trial documentation: Drug names, dates, duration, outcomes
  • Clinical guidelines support: Citations from relevant PAH guidelines
  • Monitoring plan: How you'll track response to Uptravi
From Our Advocates: We've seen step therapy exceptions approved when providers clearly document why a patient can't wait for a lengthy trial-and-error process with multiple alternatives. The key is showing medical urgency combined with specific contraindications to preferred drugs.

Switching Logistics and Provider Coordination

If you do try alternatives first, proper coordination prevents gaps in therapy and ensures safety.

Step-by-Step Switching Process

  1. Optimize Current Therapy
    • Ensure you're on maximum tolerated doses
    • Address any drug interactions
    • Stabilize other PAH treatments
  2. Plan the Transition
    • No washout periods typically required between PAH drugs
    • Gradual titration prevents rebound symptoms
    • Monitor closely during first few weeks
  3. Document Everything
    • Track symptoms, exercise tolerance, side effects
    • Record objective measures (6-minute walk test, BNP levels)
    • Note any hospitalizations or clinical worsening
  4. Provider Communication
    • Ensure PAH specialist is coordinating changes
    • Update all providers about new medications
    • Schedule follow-up within 4-6 weeks

Monitoring Requirements by Drug Class

Drug Class Key Monitoring Frequency
PDE5 Inhibitors Blood pressure, vision changes Monthly initially
ERAs Liver function tests, pregnancy tests Monthly
Prostacyclins Blood pressure, side effect tolerance Weekly during titration

Counterforce Health helps patients and providers navigate these complex switching protocols by creating detailed transition plans that address payer requirements while maintaining clinical safety.

Re-Trying for Uptravi Later

If alternatives don't work, you have strong grounds to request Uptravi approval. The key is documenting your experience thoroughly.

What to Document During Alternative Trials

  • Exact dates of therapy start/stop
  • Maximum doses achieved and duration at each dose
  • Specific side effects that led to discontinuation
  • Objective measures showing lack of improvement or worsening
  • Clinical events like hospitalizations or functional decline

Timing Your Uptravi Request

Most payers expect you to give alternatives a fair trial—typically:

  • PDE5 inhibitors: 8-12 weeks at maximum tolerated dose
  • ERAs: 12-16 weeks with proper monitoring
  • Other prostacyclins: Variable based on titration schedule

Building Your Case

When re-requesting Uptravi, your provider should submit:

  1. Summary of all previous PAH therapies with outcomes
  2. Current functional status and objective measures
  3. Clinical rationale for why Uptravi is now appropriate
  4. Updated guidelines supporting prostacyclin pathway therapy

North Carolina Appeals Process

If UnitedHealthcare denies your exception request or Uptravi after trying alternatives, North Carolina offers strong consumer protections.

Internal Appeals (UnitedHealthcare)

Timeline: 180 days from denial Process: Submit through member portal or by mail Documentation: Include all clinical records, provider letters, and guideline citations

External Review (Smart NC)

Timeline: 120 days after final internal denial Process: Submit request to Smart NC Support: Free advocacy available at 1-855-408-1212

Smart NC Success Factors:

  • Complete medical records
  • Clear documentation of medical necessity
  • Citations to recognized PAH guidelines
  • Evidence of alternative therapy failures
Tip: Smart NC advocates report higher success rates when patients submit comprehensive documentation upfront rather than piecemeal submissions.

Expedited Reviews

For urgent situations (functional class IV PAH, recent hospitalization), both UnitedHealthcare and Smart NC offer expedited reviews:

  • UHC expedited: 72 hours for urgent requests
  • Smart NC expedited: 72 hours (24-72 hours for urgent drug denials)

FAQ

How long does UnitedHealthcare prior authorization take in North Carolina? Standard PA decisions: 15 business days. Expedited requests (urgent medical need): 72 hours. Submit early to avoid therapy delays.

What if Uptravi is completely non-formulary on my plan? You can still request coverage through the exceptions process. Provide clinical documentation showing medical necessity and why formulary alternatives aren't appropriate.

Can I request expedited appeal if my PAH is worsening? Yes. If delay would seriously jeopardize your health, both UnitedHealthcare and Smart NC offer expedited reviews completed within 72 hours.

Does step therapy apply if I tried alternatives outside North Carolina? Previous therapy trials from other states typically count toward step therapy requirements. Provide complete documentation of previous treatments and outcomes.

What's the difference between prior authorization and step therapy? Prior authorization requires approval before coverage. Step therapy requires trying preferred alternatives first. Uptravi typically requires both.

How much does Uptravi cost without insurance in North Carolina? Retail prices range $9,000-$25,000 monthly depending on strength. Janssen offers patient assistance programs that may help with costs.

Can my doctor request a peer-to-peer review? Yes. If PA is denied, your provider can request to speak directly with a UnitedHealthcare medical director to discuss your case.

What happens if Smart NC overturns UnitedHealthcare's denial? The decision is binding. UnitedHealthcare must provide coverage within 3 business days of the external review decision.

When UnitedHealthcare's step therapy requirements delay access to Uptravi, understanding your alternatives and exception paths empowers you to advocate effectively. Whether working through formulary alternatives or building a case for exceptions, Counterforce Health provides the evidence-based appeals support that turns insurance denials into targeted, successful challenges to coverage restrictions.

Disclaimer: This information is for educational purposes and doesn't constitute medical advice. Always consult your healthcare provider for treatment decisions. For official appeals guidance, contact Smart NC at 1-855-408-1212.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.